Evidence map›Paper›PMID 29266294›Full record

ArticleMuscle & nerve2018

The difficulties and importance of research in rare genetic diseases.

Michael Hunter, Nicholas E Johnson

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Muscle & nerve, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Michael HunterDepartment of Neurology, University of Utah, 175 North Medical Drive, Salt Lake City, UT 84132, USA.
Nicholas E JohnsonDepartment of Neurology, University of Utah, 175 North Medical Drive, Salt Lake City, UT 84132, USA.ORCID 0000-0002-3917-4257

Funding

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)R01FD006071 · FDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Nicholas Elwood Johnson, CHARLES A THORNTON · 2017 to 2026
$3.7M
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)K23NS091511 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI JOHNSON, NICHOLAS ELWOOD · 2015 to 2019
$997k
FDA HHS R01 FD006071NINDS NIH HHS K23 NS091511
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myopathies, Structural, CongenitalHumansMedical RecordsRare DiseasesResearchRetrospective Studies

Identifiers

PMID29266294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.